Citations

Showing 10 of 108162 citations.

Great Expectations: The Dream versus the Reality of Urinary Continence and Bladder Exstrophy
Gargollo, Patricio C. , Jayanthi, R

Mayo Clinic

Journal of Urology | October 25, 2019 | Volume: 203 | Issue: 1 | Pages: 46-47

10.1097/ju.0000000000000623 | PMID 31651205 Get It

Radiation Safety Observations Associated with 177Lu Dotatate Patients
Nelson, Kevin L., Sheetz, Michael

Mayo Clinic

Health Physics | October 25, 2019 | Volume: 117 | Issue: 6 | Pages: 680-687

10.1097/hp.0000000000001122 | PMID 31652209 Get It

Abstract Lutetium-177 dotatate, marketed under the name Lutathera®, is proving to be a valuable tool for physicians treating patients with neuroendocrine somatostatin-receptive tumors. Treatment consists of four cycles of 7.4 GBq of 177 Lu dotatate infused intravenously over 30 to 40 minutes. This paper focuses on the radiation safety implications of patients undergoing 177 Lu dotatate treatments at two large medical centers in the United States under the manufacturer’s Expanded Access Protocol. Radiation safety precautions are described for the treatment of patients to control for radiation exposure and potential contamination. Ideally, the room used for administration should have a toilet, or one that is in close proximity, and covering should be provided to minimize contamination and clean up. The patient will meet the requirements in 10 CFR Part 35.75 for immediate release based on administered activity or measured exposure rate, but will need to be provided with written instruction on how to keep doses to other individuals ALARA. Disposal of the radioactive waste from 177 Lu dotatate therapy can present some hazard control issues due to the long-lived 177m Lu contaminant. Based on our experience, 177 Lu dotatate therapy is an effective outpatient procedure that can safely occur in any hospital procedural room without the need for additional local shielding. Administration can be accomplished safely with attention paid to the administration set-up and proper administration procedures. Exposure to staff or to adjacent areas is minimal.
Exertional Rhabdomyolysis: A Retrospective Population-based Study
Luetmer, Marianne T. , Boettcher, Brennan J. , Franco, John , Reisner, Jacob H. , Cheville, Andrea , Finnoff, Jonathan T.

Mayo Clinic

Medicine & Science in Sports & Exercise | October 25, 2019 | Volume: 52 | Issue: 3 | Pages: 608-615

10.1249/mss.0000000000002178 | PMID 31652234 Get It

ABSTRACT Purpose This study aimed to evaluate the incidence and characteristics of exertional rhabdomyolysis (ER) in a population-based cohort. Methods A retrospective cohort study was performed in Olmsted County, Minnesota, from 2003 to 2015. Incident ER cases were ascertained through the Rochester Epidemiology Project medical record linkage system through electronic searches of the International Classification of Diseases, Ninth Revision , codes and clinical note text. Population incidence rate was calculated using the corresponding Rochester Epidemiology Project census populations specific to calendar year and sex. Descriptive statistics were used. Results Of the 430 patients, 431 cases met the inclusion criteria for rhabdomyolysis; 4.9% of cases ( n = 20; males n = 18; Caucasian n = 17) were ER, with one recurrence. There were no deaths secondary to ER. The age- and sex-adjusted incidence rate of ER was 1.06 ± 0.24 (95% confidence interval = 0.59–1.52) per 100,000 person-years. Endurance activity ( n = 7), manual labor ( n = 5), and weight lifting ( n = 4) were common causes. Complications included kidney injury ( n = 5), mild electrolyte abnormalities ( n = 10), elevated transaminases ( n = 12), and minor electrocardiographic abnormalities ( n = 4). A majority of patients were hospitalized ( n = 16) for a median of 2 d, had mild abnormalities in renal and liver function and electrolytes, and were discharged without sequelae. Conclusion ER in the civilian population occurs at a much lower incidence than the military population. The most common causes were endurance exercise, manual labor, and weight lifting. The majority of cases were treated conservatively with intravenous fluid resuscitation during a brief hospital stay, and all were discharged without sequela. Only one case of recurrence occurred in this cohort, indicating the recurrence rate was low.
Mapping Keratoconus Molecular Substrates by Multiplexed High-Resolution Proteomics of Unpooled Corneas
Shinde, Vishal , Hu, Nan , Renuse, Santosh , Mahale, Alka, Pandey, Akhilesh , Stone, Donald U., Al-Swailem, Samar A. , Maktabi, Azza, Pandey, Akhilesh , Eberhart, Charles G. , Chakravarti, Shukti

Mayo Clinic

OMICS: A Journal of Integrative Biology | October 25, 2019 | Volume: 23 | Issue: 11 | Pages: 583-597

10.1089/omi.2019.0143 | PMID 31651220 Get It

Abstract Keratoconus (KCN) is a leading cause for cornea grafting worldwide. Keratoconus is a multifactorial disease that causes progressive thinning of the cornea and whose etiology is poorly understood. Several studies have used proteomics on patient tear fluids to identify potential biomarkers. However, proteome of the cornea itself has not been investigated fully. We report here new findings from a case–control study using multiplexed mass spectrometry (MS) on individual (unpooled) corneas to gain deeper insights into proteins and biomarkers relevant to keratoconus. We employed a high-pressure approach to extract total protein from individual corneas from five cases and five controls, followed by trypsin digestion and tandem mass tag (TMT) labeling. The MS-derived data were searched using the Human NCBI RefSeq protein database v92, with peptides and proteins filtered at 1% false discovery rate. A total of 3132 proteins were detected, of which 627 were altered significantly ( p ≤ 0.05) in keratoconus corneas. The increases were overwhelmingly in the mTOR/PI3/AKT signal-mediated regulations of cell survival and proliferation, nonsense-mediated decay of transcripts, and proteasomal pathways. The decreases were in several extracellular matrix proteins and in many members of the complement system. Importantly, this multiplexed proteomic study of keratoconus corneas identified, to our knowledge, the largest number of corneal proteins. The novel findings include changes in pathways that regulate transcript stability, proteasomal degradation, and the complement system in corneas with keratoconus. These observations offer new prospects toward future discovery of novel molecular targets for diagnostic and therapeutic innovations for patients with keratoconus.
Systemic Safety of a Recombinant AAV8 Vector for Human Cocaine Hydrolase Gene Therapy: A Good Laboratory Practice Preclinical Study in Mice
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Steele, Mike, Jenks, Nathan, Peng, Kah-Whye , Brimijoin, Stephen , Jenks, Nathan J.

Mayo Clinic

Human Gene Therapy | October 25, 2019 | Volume: 31 | Issue: 1-2 | Pages: 70-79

10.1089/hum.2019.233 | PMID 31650869 Get It

Recent Preoperative Concussion and Postoperative Complications: A Retrospective Matched-cohort Study
D’Souza, Ryan S. , Sexton, Matthew A. , Schulte, Phillip J. , Pasternak, Jeffrey J., Abcejo, Arnoley S., D'Souza, Ryan S

Mayo Clinic

Journal of Neurosurgical Anesthesiology | October 25, 2019 | Volume: 33 | Issue: 3 | Pages: 221-229

10.1097/ana.0000000000000654 | PMID 31651548 Get It

Background: Physiological alterations during the perianesthetic period may contribute to secondary neurocognitive injury after a concussion. Methods: Patients exposed to concussion and who received an anesthetic within 90 days were matched to unexposed patients without concussion. Intraoperative and postoperative events were compared. Subgroup analyses assessed relationships among patients with a concussion in the prior 30, 31 to 60, and 61 to 90 days and their respective unexposed matches. To facilitate identification of potential targets for further investigation, statistical comparisons are reported before, as well as after, correction for multiple comparisons. Results: Sixty concussion patients were matched to 176 unexposed patients. Before correction, 28.3% postconcussion versus 14.8% unexposed patients reported postanesthesia care unit pain score≥7 (P=0.02); 16.7% concussion versus 6.5% unexposed patients reported headache within 90 days of anesthesia (P=0.02) and 23.5% of patients who received surgery and anesthesia within 30 days of concussion experienced headache within 90 days of anesthesia compared with 7.1% in the unexposed group (P=0.01). Patients who experienced concussion and had anesthesia between 31 and 60 days after injury had a postanesthesia care unit Richmond Agitation and Sedation Scale score of −1.61±1.29 versus a score of −0.2±0.45 in unexposed patients (P=0.002). After adjusting the P-value threshold for multiple comparisons, the P-value for significance was instead 0.0016 for the overall cohort. Our study revealed no significant associations with application of adjusted significance thresholds. Conclusions: There were no differences in intraoperative and postoperative outcomes in patients with recent concussion compared with unexposed patients. Before correction for multiple comparisons, several potential targets for further investigation are identified. Well-powered studies are warranted.
Anesthesia During Positive-pressure Myelogram: A New Role for Cerebral Oximetry
Gatica-Moris, Sebastian R., Abcejo, Arnoley S., Pasternak, Jeffrey J., Gatica-Moris, Sebastián, Welch, Tasha L. , Carr, Carrie M.

Mayo Clinic

Journal of Neurosurgical Anesthesiology | October 25, 2019 | Volume: 33 | Issue: 3 | Pages: 263-267

10.1097/ana.0000000000000651 | PMID 31651546 Get It

Background: Positive-pressure myelogram (PPM) is an emerging radiologic study used to localize spinal dural defects. During PPM, cerebrospinal fluid pressure (CSFp) is increased by injecting saline with contrast into the cerebrospinal fluid. This has the potential to increase intracranial pressure and compromise cerebral perfusion. Methods: We performed a retrospective chart review and analysis of 11 patients. The aim was to describe the periprocedural anesthetic management of patients undergoing PPM. Results: All patients underwent PPM with general anesthesia and intra-arterial blood pressure and near-infrared spectroscopy monitoring of regional cerebral tissue oxygen saturation. Mean±SD maximum lumbar CSFp was 58±12 mm Hg. Upon intrathecal injection, mean systolic blood pressure increased from 115±21 to 142±32 mm Hg (P<0.001), diastolic blood pressure from 68±12 to 80±20 mm Hg (P≤0.001), and mean blood pressure from 87±10 to 98±14 mm Hg (P=0.02). Ten of 11 patients received blood pressure augmentation with phenylephrine to minimize the risk of reduced cerebral perfusion secondary to increased CSFp after intrathecal injection. The mean heart rate before and following injection was similar (68±15 vs. 70±15 bpm, respectively; P=0.16). There was a decrease in regional cerebral oxygen saturation after positioning from supine to prone position (79±10% to 74±9%, P=0.02) and a further decrease upon intrathecal injection (75±10% to 69±9%, P≤0.01). Conclusions: Systemic blood pressure increased following intrathecal injection during PPM, possibly due to a physiologic response to intracranial hypertension/reduced cerebral perfusion or administration of phenylephrine. Regional cerebral oxygen saturation decreased with the change to prone position and further decreased upon intrathecal injection. Cerebral near-infrared spectroscopy has a potential role to monitor the adequacy of cerebral perfusion and guide adjustment of systemic blood pressure during PPM.
Response to Propoxyphene Market Withdrawal
Jeffery, Molly M. , Morden, Nancy E., Larochelle, Marc R. , Shah, Nilay D. , Hooten, W. Michael , Meara, Ellen , Jeffery, Molly Moore

Mayo Clinic

Medical Care | October 25, 2019 | Volume: 58 | Issue: 1 | Pages: 4-12

10.1097/mlr.0000000000001221 | PMID 31651743 Get It

Objective: Experts cautioned that patients affected by the November 2010 withdrawal of the opioid analgesic propoxyphene might receive riskier prescriptions. To explore this, we compared drug receipts and outcomes among propoxyphene users before and aftermarket withdrawal. Study Design: Using OptumLabs data, we studied 3 populations: commercial, Medicare Advantage (MA) aged (age 65+ y) and MA disabled (age below 65 y) enrollees. The exposed enrollees received propoxyphene in the 3 months before market withdrawal (n=13,622); historical controls (unexposed) received propoxyphene 1 year earlier (n=9971). Regression models estimated daily milligrams morphine equivalent (MME), daily prescription acetaminophen dose, potentially toxic acetaminophen doses, nonopioid prescription analgesics receipt, emergency room visits, and diagnosed falls, motor vehicle accidents, and hip fractures. Principal Findings: Aged MA enrollees illustrate the experience of all 3 populations examined. Following the market withdrawal, propoxyphene users in the exposed cohort experienced an abrupt decline of 69% in average daily MME, compared with a 14% decline in the unexposed. Opioids were discontinued by 34% of the exposed cohort and 18% of the unexposed. Tramadol and hydrocodone were the most common opioids substituted for propoxyphene. The proportion of each group receiving ≥4 g of prescription acetaminophen per day decreased from 12% to 2% in the exposed group but increased from 6% to 8% among the unexposed. Adverse events were rare and not significantly different in exposed versus unexposed groups. Conclusions: After propoxyphene market withdrawal, many individuals experienced abrupt discontinuation of opioids. Policymakers might consider supporting appropriate treatment transitions and monitoring responses following drug withdrawals.
Increased odds of cholangiocarcinoma in Hispanics: results of a nationwide analysis
Ruiz, Jorge Nicolas, Wijarnpreecha, Karn , Harnois, Denise M. , Lukens, Frank , Wijarnpreecha, Karn , Kröner, Paul T. , Corral, Juan E.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | October 25, 2019 | Volume: 32 | Issue: 1 | Pages: 116-119

10.1097/meg.0000000000001572 | PMID 31651656 Get It

Objective Cholangiocarcinoma (CCA) affects all ethnicities worldwide. The Hispanic population being the leading ethnic minority in the United States, its importance to the healthcare system cannot be understated. This study aims to assess the occurrence and outcomes of CCA in Hispanic patients in the United States. Methods This is a case-control study using the National Inpatient Sample 2014. All patients with ICD-9 CM codes for CCA were included. Hispanic patients were identified from the ethnic categories within the database. The primary outcomes were the occurrence and odds of CCA in the Hispanic population when compared with other ethnicities. Secondary outcomes were inpatient mortality, morbidity, ICU stay, multiorgan failure, and resource utilization. Results A total of 13 965 patients with CCA were identified, of which 2750 were propensity-matched to controls (1480 Hispanic). The inpatient occurrence of CCA in Hispanics relative to the national population was 2.73/100 000 persons, compared to 4.82/100 000 persons (39.9/100 000 relative to inpatient population) of all other ethnicities. After adjusting for confounders on multivariate analysis, Hispanic patients displayed adjusted propensity-matched odds of 1.28 (P < 0.01) of having CCA when compared with other ethnicities. Hispanics did not display different propensity-matched odds of inpatient mortality, morbidity, hospital length of stay, or resource utilization compared to non-Hispanic patients. Conclusion This study demonstrated that the odds of CCA in admitted patients are higher for the Hispanic population. This difference with the prevalence potentially suggests the presence of social factors such as disparities in cancer prevention or detection in this group.
Using Cerebral Metabolites to Guide Precision Medicine for Subarachnoid Hemorrhage: Lactate and Pyruvate
Zahra, Kaneez , Gopal, Neethu , Turnbull, Marion T. , Turnbull, Marion T , Freeman, William D.

Mayo Clinic

Metabolites | October 25, 2019 | Volume: 9 | Issue: 11 | Pages: 245

10.3390/metabo9110245 | PMID 31652842 Get It

Subarachnoid hemorrhage (SAH) is one of the deadliest types of strokes with high rates of morbidity and permanent injury. Fluctuations in the levels of cerebral metabolites following SAH can be indicators of brain injury severity. Specifically, the changes in the levels of key metabolites involved in cellular metabolism, lactate and pyruvate, can be used as a biomarker for patient prognosis and tailor treatment to an individual’s needs. Here, clinical research is reviewed on the usefulness of cerebral lactate and pyruvate measurements as a predictive tool for SAH outcomes and their potential to guide a precision medicine approach to treatment.